Abstract
For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds
Volume: 21 Issue: 30
Author(s): Hayrettin O. Gulcan*Ilkay E. Orhan*
Affiliation:
- Faculty of Pharmacy, Eastern Mediterranean University, Famagusta, T.R. North Cyprus, via Mersin 10,Turkey
- Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara,Turkey
Keywords: Alzheimer's disease, Parkinson’s disease, Dual inhibitors, Monoamine oxidase, Cholinesterase, Heterocyclic scaffolds.
Abstract: For the last two decades, there has been research interest on the design of molecules possessing dual inhibitory potential on cholinesterase and monoamine oxidase enzymes, particularly for the treatment of two major neurodegenerative diseases, Alzheimer’s Disease (AD) and Parkinson’s disease (PD). Many compounds have been synthesized for this purpose, and some of them have been shown to display activities comparable or superior to the activities of current drugs used for the treatment of AD and PD. Within the concept of this review study, we have aimed to present the current drugs used for the treatment of AD and PD, their mechanism of action, the discussion behind the theory of designing dual inhibitor agents, and the presentation of the most active compounds with diverse heterocyclic scaffolds displayed in research studies published in the recent period.
Export Options
About this article
Cite this article as:
Gulcan O. Hayrettin *, Orhan E. Ilkay *, Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds, Current Topics in Medicinal Chemistry 2021; 21 (30) . https://dx.doi.org/10.2174/1568026621666210902121148
DOI https://dx.doi.org/10.2174/1568026621666210902121148 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets Multiple Mechanisms of Cytokine Action in Neurodegenerative and Psychiatric States: Neurochemical and Molecular Substrates
Current Pharmaceutical Design Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews Therapeutic Role of Zonisamide in Neuropsychiatric Disorders
Mini-Reviews in Medicinal Chemistry Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Current Protein & Peptide Science Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Is Ecto-nucleoside Triphosphate Diphosphohydrolase (NTPDase)-based Therapy of Central Nervous System Disorders Possible?
Mini-Reviews in Medicinal Chemistry Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Molecular Imaging of Stem Cell Transplantation for Neurodegenerative Diseases
Current Pharmaceutical Design Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Midkine and Pleiotrophin in the Treatment of Neurodegenerative Diseases and Drug Addiction
Recent Patents on CNS Drug Discovery (Discontinued) Kinases as Targets for Parkinson's Disease: From Genetics to Therapy
CNS & Neurological Disorders - Drug Targets Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Current Medicinal Chemistry Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Current Pharmaceutical Design Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research